Bio-Techne CEO exercises options, delivers shares for tax
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 26,692 shares of common stock on May 5, 2026.
Rhea-AI Filing Summary
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 26,692 shares of common stock on May 5, 2026. The options had an exercise price of $47.60 per share, resulting in the acquisition of 26,692 common shares. On the same date, 23,951 common shares were delivered to satisfy tax obligations at $56.68 per share. After these transactions, Kelderman directly holds 65,799 common shares, 176,668 Stock Option (Right to Buy) awards, 307,975 additional Stock Options (Right to Buy), 49,826 Performance Stock Options, 140,265 Performance Restricted Stock Units, and 52,441 Restricted Stock Units.
Positive
- None.
Negative
- None.
Insider Trade Summary
26,692 shares exercised/converted
Exercise
19 txns
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 26,692 | $0.00 | $0.00 |
| Exercise | Common Stock | 26,692 | $47.60 | $1.27M |
| Exercise Price or Tax Liability | Common Stock | 23,951 | $56.68 | $1.36M |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 176,668 contracts for 141,668 underlying shares (Direct);
Common Stock — 65,799 shares (Direct);
Stock Options (Right to Buy) — 307,975 contracts (Direct);
Performance Restricted Stock Units — 140,265 contracts (Direct);
Performance Stock Options (Right to Buy) — 49,826 contracts (Direct);
Restricted Stock Units — 52,441 contracts (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F3. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F4. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F5. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F6. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- F9. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Options Exercised: 26,692 shares
Exercise Price: $47.60 per share
Shares Delivered for Taxes: 23,951 shares
+5 more
8 metrics
Options Exercised
26,692 shares
Stock Option (Right to Buy) exercised into common stock on 2026-05-05
Exercise Price
$47.60 per share
Price for exercising options into 26,692 common shares
Shares Delivered for Taxes
23,951 shares
Common shares delivered to satisfy tax obligations at $56.68 per share
Tax Withholding Price
$56.68 per share
Value used for payment of tax liability via share delivery
Common Stock Holding
65,799 shares
Direct BIO-TECHNE common stock held by Kim Kelderman after transactions
Stock Option Holdings
176,668 options
Direct holding of Stock Option (Right to Buy) after transactions
Additional Stock Options
307,975 options
Direct holding of Stock Options (Right to Buy) after transactions
Performance RSU Holdings
140,265 units
Direct Performance Restricted Stock Units linked to BIO-TECHNE common stock
Key Terms
tax-withholding disposition, Performance Restricted Stock Units, derivative security, Fully exercisable
4 terms
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
Performance Restricted Stock Units financial
"Performance Restricted Stock Units, underlying security title Common Stock"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Fully exercisable financial
"Fully exercisable."
FAQ
What did BIO-TECHNE (TECH) CEO Kim Kelderman report on May 5, 2026?
Kim Kelderman exercised 26,692 stock options for common stock at $47.60 per share and delivered 23,951 shares at $56.68 per share to cover tax obligations, updating her direct equity holdings in BIO-TECHNE.
What are Kim Kelderman’s direct common stock holdings in BIO-TECHNE (TECH) after the transactions?
Following the reported transactions, Kelderman directly holds 65,799 common shares of BIO-TECHNE. In addition, she retains substantial option and restricted stock unit positions representing further potential equity in the company.
What derivative and RSU positions does BIO-TECHNE (TECH) CEO Kelderman still hold?
Post-transaction, Kelderman holds 176,668 Stock Option (Right to Buy), 307,975 Stock Options (Right to Buy), 49,826 Performance Stock Options, 140,265 Performance Restricted Stock Units, and 52,441 Restricted Stock Units, all directly tied to BIO-TECHNE common stock.
Were Kelderman’s BIO-TECHNE (TECH) transactions under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is unchecked, indicating the reported option exercise and tax-withholding share delivery were not affirmed as executed under a pre-arranged Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
